BACKGROUND: In light of the increasing trend in the global number of individuals affected by dementia and the lack of any available disease-modifying therapies, it is necessary to fully understand and quantify the global burden of dementia. This work aimed to estimate the proportion of dementia due to Down syndrome, Parkinson's disease, clinical stroke, and traumatic brain injury (TBI), globally and by world region, in order to better understand the contribution of clinical diseases to dementia prevalence. METHODS: Through literature review, we obtained data on the relative risk of dementia with each condition and estimated relative risks by age using a Bayesian meta-regression tool. We then calculated population attributable fractions (PAFs), or the proportion of dementia attributable to each condition, using the estimates of relative risk and prevalence estimates for each condition from the Global Burden of Disease Study 2019. Finally, we multiplied these estimates by dementia prevalence to calculate the number of dementia cases attributable to each condition. FINDINGS: For each clinical condition, the relative risk of dementia decreased with age. Relative risks were highest for Down syndrome, followed by Parkinson's disease, stroke, and TBI. However, due to the high prevalence of stroke, the PAF for dementia due to stroke was highest. Together, Down syndrome, Parkinson's disease, stroke, and TBI explained 10.0% (95% UI: 6.0-16.5) of the global prevalence of dementia. INTERPRETATION: Ten percent of dementia prevalence globally could be explained by Down syndrome, Parkinson's disease, stroke, and TBI. The quantification of the proportion of dementia attributable to these 4 conditions constitutes a small contribution to our overall understanding of what causes dementia. However, epidemiological research into modifiable risk factors as well as basic science research focused on elucidating intervention approaches to prevent or delay the neuropathological changes that commonly characterize dementia will be critically important in future efforts to prevent and treat disease.

Zobrazit více v PubMed

Prince MJ. World Alzheimer report 2015: the global impact of dementia [Internet]. 2015. Aug [cited 2018 Apr 8]. Available from: https://www.alz.co.uk/research/world-report-2015.

Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013. Jan;9(9):63–e2. PubMed

Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019. Jan;18(1): 88–106. PubMed PMC

Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007. Jul;3(3):186–91. PubMed

Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013. May;80(19):1778–83. PubMed PMC

Matthews KA, Xu W, Gaglioti AH, Holt JB, Croft JB, Mack D, et al. Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015–2060) in adults aged ≥65 years. Alzheimers Dementia. 2019. Jan;15(1):17–24. PubMed PMC

Waite LM. Treatment for Alzheimer’s disease: has anything changed? Aust Prescr. 2015. Apr;38(2):60–3. PubMed PMC

Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020. Aug; 396(10248):413–46. PubMed PMC

Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P. Epidemiological pathology of dementia: attributable-risks at death in the medical research council cognitive function and ageing study. PLoS Med. 2009. Nov; 6(6):e1000180. PubMed PMC

Brayne C, Richardson K, Matthews FE, Fleming J, Hunter S, Xuereb JH, et al. Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75s Cohort (CC75C) Study. J Alzheimers Dis. 2009. Jan; 18(3):645–58. PubMed

Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med. 2009. May; 360(22):2302–9. PubMed

Barba R, Martínez-Espinosa S, Rodríguez-García E, Pondal M, Vivancos J, Del Ser T. Poststroke dementia: clinical features and risk factors. Stroke. 2000. Jul;31(7):1494–501. PubMed

Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, Mcarthur J. Evolution of HIV dementia with HIV infection. Int Rev Psychiatry. 2008. Jan;20(20):25–31. PubMed

Oliver C, Holland AJ. Down’s syndrome and Alzheimer’s disease: a review. Psychol Med. 1986. May;16(2):307–22. PubMed

Lye TC, Shores EA. Traumatic brain injury as a risk factor for Alzheimer’s disease: a review. Neuropsychol Rev. 2000. Jun;10(2):115–29. PubMed

Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005. Oct; 20(10):1255–63. PubMed

Kuźma E, Lourida I, Moore SF, Levine DA, Ukoumunne OC, Llewellyn DJ. Stroke and dementia risk: a systematic review and metaanalysis. Alzheimers Dement. 2018. Nov; 14(14):1416–26. PubMed PMC

Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer’s disease in down’s syndrome. Ann Neurol. 1985;17(3): 278–82. PubMed

Hicks AJ, James AC, Spitz G, Ponsford JL. Traumatic brain injury as a risk factor for dementia and Alzheimer disease: critical review of study methodologies. J Neurotrauma. 2019. Aug;36(23):3191–219. PubMed

Mukadam N, Sommerlad A, Huntley J, Livingston G. Population attributable fractions for risk factors for dementia in low-income and middle-income countries: an analysis using cross-sectional survey data. Lancet Glob Health. 2019. May;7(7):e596–603. PubMed PMC

World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidlines. Geneva: World Health Organization; 1992.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington D.C.; 2000.

Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020. Oct;396(10258): 1204–22. PubMed PMC

Wang H, Abbas KM, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, et al. Global, age-sex-specific fertility, mortality, healthy life expectancy (HALE) and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet. 2020. Oct;396(10258): 1160–203. PubMed PMC

Dams-O’Connor K, Guetta G, Hahn-Ketter AE, Fedor A. Traumatic brain injury as a risk factor for Alzheimer’s disease: current knowledge and future directions. Neurodegener Dis Manag. 2016;6(5):417–29. PubMed PMC

Perry DC, Sturm VE, Peterson MJ, Pieper CF, Bullock T, Boeve BF, et al. Association of traumatic brain injury with subsequent neurological and psychiatric disease: a metaanalysis. J Neurosurg. 2016. Feb;124(124): 511–26. PubMed PMC

Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol. 1974. May;99(5): 325–32. PubMed

Ballard C, Mobley W, Hardy J, Williams G, Corbett A. Dementia in Down’s syndrome. Lancet Neurol. 2016. May;15(15):622–36. PubMed

Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Deerlin VV, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012;72(4):587–98. PubMed PMC

Johnson CO, Nguyen M, Roth GA, Nichols E, Alam T, Abate D, et al. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019. May; 18(5):439–58. PubMed PMC

Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005. Oct;62(10):1556–60. PubMed

Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff. 2007. Jan–Feb;26(1):13–24. PubMed PMC

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8(6):595–608. PubMed PMC

Mandelkow EM, Mandelkow E. Tau in Alzheimer’s disease. Trends Cell Biol. 1998. Nov; 8(11):425–7. PubMed

Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. Alphasynuclein in Lewy bodies. Nature. 1997. Aug; 388(6645):839–40. PubMed

Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007. Dec;69(69): 2197–204. PubMed

James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia. Brain. 2016. Nov;139(11): 2983–93. PubMed PMC

Murray CJL, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013. Aug; 369(5):448–57. PubMed

Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007. Oct;69(18):1789–99. PubMed PMC

Corraini P, Henderson VW, Ording AG, Pedersen L, Horváth-Puhó E, Sørensen HT. Long-term risk of dementia among survivors of ischemic or hemorrhagic stroke. Stroke. 2017;48(48):180–6. PubMed PMC